Business Context and Reporting Period
Company: Techne Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended December 31, 1996
Operations: The Company operates through two primary subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. in Abingdon, England. Operations are divided into Biotechnology (cytokines, antibodies, assay kits) and Hematology (controls and calibrators) divisions.
Key Financial Metrics
| Metric | Quarter Ended 12/31/96 | Six Months Ended 12/31/96 |
|---|---|---|
| Net Sales | $14,409,294 | $28,436,272 |
| Gross Margin | $9,837,582 (68.3%) | $19,086,430 (67.1%) |
| Net Earnings | $2,277,491 | $4,452,760 |
| Earnings Per Share (Diluted) | $0.23 | $0.46 |
| Cash & Cash Equivalents | $6,953,881 | $6,953,881 (Balance Sheet) |
| Short-term Investments | $12,862,451 | $12,862,451 (Balance Sheet) |
| Total Current Assets | $33,496,918 | $33,496,918 (Balance Sheet) |
| Total Current Liabilities | $5,063,172 | $5,063,172 (Balance Sheet) |
| Operating Cash Flow (6mo) | N/A | $6,016,773 |
| Capital Additions (6mo) | N/A | $3,418,612 |
Liquidity: Total liquid assets (cash and short-term investments) totaled $19,816,332 as of December 31, 1996. The Company maintains an unsecured line of credit of $750,000 with no borrowings outstanding.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15% for the quarter and 12% for the six-month period compared to the prior year. Growth was driven by a 43% increase in cytokine/antibody sales and a 15% increase in immunoassay kit sales.
- Margin Expansion: Gross margins improved to 68.3% (quarter) and 67.1% (six months) from 63.0% and 63.3% in the prior year. This was attributed to a shift toward higher-margin biotechnology products and the cessation of royalty payments to Amgen Inc. in August 1996.
- Profitability: Net earnings increased 35% for the quarter and 28% for the six months. Earnings before taxes rose primarily due to increased performance in the Biotechnology Division and R&D Europe.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 16% (quarter) due to bonus accruals, additional staff, and advertising. Research and development (R&D) expenses increased 20% (quarter) to support new product development.
- Hematology Decline: Hematology product sales decreased due to the loss of an OEM customer, though this was partially offset by higher retail sales.
Guidance, Outlook, and Risks
Capital Expenditures: The Company expects to spend approximately $3.1 million on capital additions for the remainder of fiscal 1997, primarily for facility expansion and equipment, funded by existing cash and operating cash flow.
Share Repurchases: The Company continues a program to repurchase up to $5,000,000 of common stock. As of February 1, 1997, $3,177,786 worth of shares had been retired. No dividends are planned.
Risks and Contingencies:
- Market acceptance of new biotechnology and hematology products.
- Price competition from a growing number of cytokine producers.
- Retention of hematology OEM and proficiency survey business.
- Impact of exchange rate fluctuations on European operations (noted impact on SG&A expenses).
Investor Verification Checklist
- Revenue Mix: Verify the sustainability of the shift toward higher-margin biotechnology products (84% of sales) versus the declining hematology segment.
- Customer Concentration: Assess the impact of the lost OEM customer in the Hematology division and the reliance on R&D Europe for distribution (69% of R&D Europe sales are R&D Systems products).
- Capital Allocation: Monitor the execution of the $3.1 million planned capital expenditure and the progress of the $5 million share repurchase program.
- Foreign Exchange: Review the sensitivity of European earnings and expenses to USD/GBP exchange rate fluctuations.
- Debt Status: Confirm the continued absence of borrowings against the $750,000 line of credit.